Sovaldi In Medicaid: Contractor Molina Urges Government To Assume Up-Front Cost
Executive Summary
Medicaid managed care organization Molina says its 2014 payment rates are not adequate to cover the cost of Gilead Sciences’ hepatitis C drug Sovaldi and that the government should handle the upfront costs. WellPoint’s Medicaid plans have seen a 50% increase in the cost of treating hepatitis C patients.
You may also be interested in...
Medicaid Coverage For Gilead’s Sovaldi “Imprudent” Unless Price Reduced – Patient Group
In response to price concerns with Sovaldi, Gilead Sciences emphasized that “Medicaid, by law, receives very deep discounts, and Gilead is working with each state to complete the necessary steps to ensure a timely review and addition to the state formulary.”
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.
Biden vs Trump On Drug Pricing And Unfinished Business
While more significant reforms are less likely under a second Biden term unless Democrats control both chambers of Congress, former President Trump could look to put his stamp on drug pricing reform by resurrecting one of his former policies involving international reference pricing and Medicare Part B drugs.